EXEL
Exelixis, Inc.
NASDAQ · USHealthcareBiotechnology
$55.53-0.70%
Price as of Jul 20, 2026
EXEL financials
Exelixis, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2026 | 2025 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $2.3B | $2.2B | $1.8B | $1.6B |
| Cost of revenue | $83.7M | $76.2M | $72.5M | $57.9M |
| Gross profit | $2.2B | $2.1B | $1.8B | $1.6B |
| Operating expenses | $1.4B | $1.5B | $1.6B | $1.4B |
| Operating income | $872.2M | $604.6M | $170.9M | $201.5M |
| Net income | $782.6M | $521.3M | $207.8M | $182.3M |
| EBITDA | $921.8M | $718.8M | $283.2M | $255.2M |
| Basic EPS | $2.88 | $1.80 | $0.65 | $0.57 |
| Diluted EPS | $2.78 | $1.76 | $0.65 | $0.56 |
| Balance sheet | ||||
| Cash & equivalents | $482.5M | $217.4M | $263.0M | $501.2M |
| Total assets | $2.8B | $2.9B | $2.9B | $3.1B |
| Total liabilities | $683.1M | $703.5M | $678.4M | $583.1M |
| Stockholders’ equity | $2.2B | $2.2B | $2.3B | $2.5B |
| Total debt | $173.0M | $190.8M | $189.9M | $190.2M |
| Net debt | -$309.4M | -$26.6M | -$73.0M | -$311.0M |
| Cash flow | ||||
| Operating cash flow | $884.3M | $700.0M | $333.3M | $362.6M |
| Capital expenditure | -$39.9M | -$66.2M | -$163.0M | -$138.5M |
| Free cash flow | $844.3M | $633.8M | $170.4M | $224.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$947.5M | -$652.0M | -$550.4M | $0.00 |